News

Contact Us

Address:
Mirai Medical
Unit 5, Howley Court
Oranmore
Galway
Ireland

ePORE^® therapy, EndoVE^® and CUTIS are approved for commercialisation in the European Union, United Kingdom and Australia. ePORE^® therapy, EndoVE^® and CUTIS are not cleared by FDA for commercialisation in the USA.

Website by Proactive Design & Marketing

Mirai Medical attends the Australasian Melanoma Conference (AMC) 2023

Mirai Medical treats the first skin cancer patient in Australia with ePORE^® therapy

The first clinical paper published using electroporation in conjunction with calcium for the treatment of colorectal cancer

First live surgery demonstration of Mirai Medical’s ePORE^® therapy for the treatment of gastrointestinal cancers

Mirai Medical appoints Paraic Curtis to the board

First patient with oesophageal cancer is treated in Germany using ePORE^® therapy with EndoVE^®

Mirai Medical’s ePORE^® therapy with EndoVE^® is launched in Spain

Mirai Medical launch EndoVE^® probe in Leeds

Mirai Medical Launches its New Website and has Received a Favourable Ethical Opinion for the PIONEER Patient Registry

First Patient Enrolled in VECTOR Trial using ePORE^® therapy for the Treatment of Inoperable Oesophageal and Gastric Cancer

Contact Us